Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Hou, Hsin-An  [Clear All Filters]
Journal Article
Wang Y-H, Lin C-C, Yao C-Y, Hsu C-L, Hou H-A, Tsai C-H, Chou W-C, Tien H-F. A 4-gene leukemic stem cell score can independently predict the prognosis of myelodysplastic syndrome patients. Blood Adv. 2020;4(4):644-654.
Chen Y-K, Hou H-A, Tang J-L, Jhuang J-Y, Lai Y-J, Lee M-C, Kuo Y-Y, Chou W-C, Liu C-Y, Lin C-W, et al. Clinical and Prognostic Implications of Roundabout 4 (Robo4) in Adult Patients with Acute Myeloid Leukemia. PLoS One. 2015;10(3):e0119831.
Hung S-Y, Lin C-C, Hsu C-L, Yao C-Y, Wang Y-H, Tsai C-H, Hou H-A, Chou W-C, Tien H-F. The expression levels of long non-coding RNA KIAA0125 are associated with distinct clinical and biological features in myelodysplastic syndromes. Br J Haematol. 2020.
Tang J-L, Kung H-C, Lei W-C, Yao M, Wu U-I, Hsu S-C, Lin C-T, Li C-C, Wu S-J, Hou H-A, et al. High Incidences of Invasive Fungal Infections in Acute Myeloid Leukemia Patients Receiving Induction Chemotherapy without Systemic Antifungal Prophylaxis: A Prospective Observational Study in Taiwan. PLoS One. 2015;10(6):e0128410.
McGraw KL, Cheng C-H, Y Chen A, Hou H-A, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, et al. Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis. Blood Adv. 2019;3(22):3579-3589.
Kuo Y-Y, Hou H-A, Chen Y-K, Li L-Y, Chen P-H, Tseng M-H, Huang C-F, Lee F-Y, Liu M-C, Liu C-W, et al. The N-terminal CEBPA mutant in acute myeloid leukemia impairs CXCR4 expression. Haematologica. 2014.
Cheng C-L, Li C-C, Hou H-A, Fang W-Q, Chang C-H, Lin C-T, Tang J-L, Chou W-C, Chen C-Y, Yao M, et al. Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults. BMC Cancer. 2015;15(1):344.
Hou H-A, Liu C-Y, Kuo Y-Y, Chou W-C, Tsai C-H, Lin C-C, Lin L-I, Tseng M-H, Chiang Y-C, Liu M-C, et al. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget. 2016.
Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, Geyer S, Hou H-A, Eksioglu EAdriana, Sullivan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020.